Should I buy or sell Cidara Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDTX shares. View CDTX analyst ratings or view top-rated stocks .

What is Cidara Therapeutics' stock price target for 2024?

3 equities research analysts have issued 1-year price objectives for Cidara Therapeutics' shares. Their CDTX share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.67 in the next twelve months. This suggests a possible upside of 508.8% from the stock's current price. View analysts price targets for CDTX or view top-rated stocks among Wall Street analysts .

How have CDTX shares performed in 2024?

Cidara Therapeutics' stock was trading at $0.7940 at the beginning of 2024. Since then, CDTX shares have decreased by 3.5% and is now trading at $0.7665. View the best growth stocks for 2024 here .

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 195,400 shares, an increase of 8.9% from the March 15th total of 179,500 shares. Based on an average daily trading volume, of 671,800 shares, the short-interest ratio is currently 0.3 days. View Cidara Therapeutics' Short Interest .

When is Cidara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CDTX earnings forecast .

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. The biotechnology company had revenue of $7.08 million for the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 264.84% and a negative net margin of 55.49%.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Verastem (VSTM) , Dynavax Technologies (DVAX) , Micron Technology (MU) , Exelixis (EXEL) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX) .

When did Cidara Therapeutics IPO?

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CDTX

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free CDTX Stock Alerts

$0.77

-0.06 (-7.06%)

(As of 01:50 PM ET)

Compare

Today's Range: $0.74
▼
$0.87
50-Day Range: $0.64
▼
$1.16
52-Week Range: $0.59
▼
$1.48

Volume: 912,923 shs
Average Volume: 659,821 shs
Market Capitalization: $69.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.67

Get Cidara Therapeutics alerts:

Cidara Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 508.8% Upside
$4.67 Price Target
Short Interest: Healthy
0.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.31
Based on 5 Articles This Week
Insider Trading: Selling Shares
$40,490 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.28) to ($0.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

220th out of 930 stocks

Biological Products, Except Diagnostic Industry

27th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cidara Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.22% of the outstanding shares of Cidara Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Cidara Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cidara Therapeutics has recently increased by 8.86%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cidara Therapeutics does not currently pay a dividend.
Dividend Growth
Cidara Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Cidara Therapeutics is -0.85.

3.0

News and Social Media Coverage

News Sentiment
Cidara Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Cidara Therapeutics this week, compared to 1 article on an average week.
Search Interest
11 people have searched for CDTX on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.
MarketBeat Follows
5 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,490.00 in company stock.
Percentage Held by Insiders
Only 7.43% of the stock of Cidara Therapeutics is held by insiders.
Percentage Held by Institutions
Only 35.82% of the stock of Cidara Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cidara Therapeutics are expected to decrease in the coming year, from ($0.28) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cidara Therapeutics is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cidara Therapeutics is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CDTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDTX Stock News Headlines

April 14, 2024 | seekingalpha.com

CDTX Cidara Therapeutics, Inc.

April 9, 2024 | americanbankingnews.com

Cidara Therapeutics (NASDAQ:CDTX) Receives "Buy" Rating from HC Wainwright

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

April 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments

April 7, 2024 | investing.com

Cidara Therapeutics reveals promising cancer therapy data

April 5, 2024 | globenewswire.com

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 17, 2024 | finance.yahoo.com

Cidara Therapeutics, Inc. (CDTX)

March 9, 2024 | edition.cnn.com

Cidara Therapeutics, Inc.

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

March 6, 2024 | finance.yahoo.com

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024

March 6, 2024 | globenewswire.com

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

February 15, 2024 | finance.yahoo.com

Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio

February 12, 2024 | msn.com

Cidara receives $11M milestone payment from partner Mundipharma

February 12, 2024 | marketwatch.com

Cidara Therapeutics Gets $11.1M Milestone Payment for Rezzayo

February 12, 2024 | markets.businessinsider.com

Cidara Receives Milestone Payment From Mundipharma On European Approval Of REZZAYO

February 12, 2024 | finance.yahoo.com

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

February 10, 2024 | markets.businessinsider.com

Cidara Therapeutics Granted Nasdaq Listing Extension

January 30, 2024 | finanznachrichten.de

Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

January 30, 2024 | msn.com

Palatin to raise ~$10M via securities offering

January 29, 2024 | marketwatch.com

Cidara Therapeutics Gets UK Watchdog's Approval for Invasive Candidiasis Treatment

January 29, 2024 | marketwatch.com

Cidara Therapeutics Shares Up 14% After UK Approval of Invasive Candidiasis Infection Treatment

January 29, 2024 | msn.com

Cidara rallies 13% after hours on UK approval for Rezzayo

January 29, 2024 | finance.yahoo.com

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

December 22, 2023 | markets.businessinsider.com

Cidara Therapeutics : EU Approves Rezzayo For Treatment Of Invasive Candidiasis In Adults

December 22, 2023 | finance.yahoo.com

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

December 21, 2023 | benzinga.com

Cidara Therapeutics Stock (NASDAQ:CDTX) Dividends: History, Yield and Dates

December 7, 2023 | finance.yahoo.com

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

See More Headlines

Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CDTX
CUSIP: N/A
CIK: 1610618
Web: www.cidara.com
Phone: (858) 752-6170
Fax: N/A
Employees: 73
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.67
High Stock Price Target: $6.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +465.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,800,000.00
Net Margins: -55.49%
Pretax Margin: -53.14%
Return on Equity: -264.84%
Return on Assets: -48.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.62
Quick Ratio: 1.55

Sales & Book Value

Annual Sales: $56.54 million
Price / Sales: 1.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.04) per share
Price / Book: -20.62

Miscellaneous

Outstanding Shares: 90,619,000
Free Float: 83,886,000
Market Cap: $74.73 million
Optionable: Optionable
Beta: 0.98

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Jeffrey L. Stein Ph.D. (Age 69)
President, CEO & Executive Director
Comp: $873.25k
Dr. Preetam Shah M.B.A. (Age 51)
Ph.D., CFO, Chief Business Officer & Principal Accounting Officer
Comp: $577.85k
Dr. Taylor Sandison (Age 52)
Chief Medical Officer
Comp: $632.05k
Dr. Kevin M. Forrest Ph.D. (Age 47)
Founder and Chief Strategy Officer
Comp: $333.31k
Mr. Shane M. Ward (Age 49)
COO & Chief Legal Officer
Ms. Allison Lewis CCP
SPHR, Senior Vice President of People & Culture
Dr. Leslie Tari Ph.D. (Age 57)
Chief Scientific Officer
Comp: $845.1k
Ms. Laura A. Navalta
Senior Vice President of Clinical Operations
Dr. Nicole Davarpanah J.D.
M.D., Senior VP of Translational Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings or view top-rated stocks.
What is Cidara Therapeutics' stock price target for 2024?: 3 equities research analysts have issued 1-year price objectives for Cidara Therapeutics' shares. Their CDTX share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.67 in the next twelve months. This suggests a possible upside of 508.8% from the stock's current price.
View analysts price targets for CDTX or view top-rated stocks among Wall Street analysts.
How have CDTX shares performed in 2024?: Cidara Therapeutics' stock was trading at $0.7940 at the beginning of 2024. Since then, CDTX shares have decreased by 3.5% and is now trading at $0.7665.
View the best growth stocks for 2024 here.
Are investors shorting Cidara Therapeutics?: Cidara Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 195,400 shares, an increase of 8.9% from the March 15th total of 179,500 shares. Based on an average daily trading volume, of 671,800 shares, the short-interest ratio is currently 0.3 days.
View Cidara Therapeutics' Short Interest.
When is Cidara Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CDTX earnings forecast.

How were Cidara Therapeutics' earnings last quarter?: Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. The biotechnology company had revenue of $7.08 million for the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 264.84% and a negative net margin of 55.49%.
What other stocks do shareholders of Cidara Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).
When did Cidara Therapeutics IPO?: Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.
How do I buy shares of Cidara Therapeutics?: Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

Cidara Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cidara Therapeutics Stock (NASDAQ:CDTX)

CDTX Stock Price History

CDTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CDTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™